Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
66.69
+0.10 (+0.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
January 30, 2023
From
Gilead Sciences, Inc. and Arcellx, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
January 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
Mount Gilead, NC Author Publishes Children's Book
January 12, 2023
So Excited, She Runs To Solve The Mystery Of What She Is Smelling.
Via
PR Leap
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
January 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
January 13, 2023
Global Cell and Gene Therapy Market will worth USD 21,508 million by 2028-end at a CAGR of 28.2% from 2022 to 2028 according to Intelligence Market Report
Via
SBWire
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
December 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
December 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
December 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
December 19, 2022
From
Arcus Biosciences
Via
Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
December 14, 2022
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.
Via
MarketBeat
Gilead Sciences Again Named to Dow Jones Sustainability World Index
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
December 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
December 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
December 08, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NYSE:BMY),(NASDAQ:RXDS),(NASDAQ:RNAZ) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
December 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
November 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-small Cell Lung Cancer
November 28, 2022
From
Arcus Biosciences
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
November 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
November 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
November 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.